Otsuka Pharmaceutical (TYO:4578) said today it inked a collaborative deal with health management group Magellan Health to distribute its drug-device combo Abilify Mycite in the US.
The Tokyo-based pharmaceutical company touted the Abilify Mycite system as the first FDA-approved drug-device combo designed to track drug ingestion, and said that the tracking data will be integrated into Magellan Health’s mental health provider network.
Read the whole story on our sister site, Drug Delivery Business News
The post Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US appeared first on MassDevice.
from MassDevice https://ift.tt/2NywrTT
Cap comentari:
Publica un comentari a l'entrada